Targeting residual inflammatory risk across the full spectrum of atherosclerotic disease is the next frontier for atherosclerosis treatment and prevention.
In patients with residual inflammatory risk, based on guidelines, low-dose colchicine can be added to statin therapy as well as to background therapies that might include multiple other adjunctive lipid lowering agents.
Trials are in planning or underway evaluating interleukin-6 inhibition in the settings of chronic kidney disease, heart failure with preserved ejection fraction, acute coronary ischemia, and hemodialysis.
The ARTEMIS trial is about to start. It is a phase 3, event-driven trial of approximately 10000 patients with recent type 1 acute myocardial infarction, who will be randomized to the anti-IL-6 monoclonal antibody ziltivekimab or placebo, on top of standard of care. The primary endpoint is a composite of cardiovascular death, myocardial infarction, or stroke.
Hace 31 años, un equipo único en la historia del básquetbol ganaba el oro en Barcelona 1992. Hablamos, por supuesto, del irreproducible y surrealista Dream Team. Michael Jordan, Magic Johnson y Larry Bird juntos. Extraterrestres contra seres humanos. El mito de la NBA que desciende al planeta tierra. El sueño de David Stern en marcha: viajemos, entonces, con un ticket dorado hacia el pasado. Abro hilo.
👕 ¡SORTEAMOS LA CAMISETA FIRMADA POR NUESTRO CAMPEÓN DEL MUNDO! 🔥
¿Cómo participar?
1. Seguir a @PSG_espanol
2. Dar RT a este tuit
3. ¡Mucha suerte!
¡VAMOS, PARIS! ❤️💙